Skip to main content
. Author manuscript; available in PMC: 2016 Jan 15.
Published in final edited form as: Horm Metab Res. 2012 Mar 7;44(5):367–372. doi: 10.1055/s-0031-1299712

Table 1.

Sensitivity of functional imaging.

Nonmetastatic PPGL (20 patients)
CT and/or MRI 18F-DOPA 18F-FDA 123I-MIBG 18F-FDG
With ref. to histologically confirmed lesions 100 % (26/26) 81 % (21/26) 77 % (20/26) 77 % (20/26) 88 % (23/26)
Sensitivities are not significantly different between functional imaging modalities
Metastatic PPGL (28 patients)
CT and/or MRI 18F-DOPA A 18F-FDA B 123I-MIBG C 18F-FDG D
With ref. to lesions on CT and/or MRI – 45 % (96/211) 76 % (161/211) 57 % (106/187) 74 % (157/211)

Adapted with permission from [12], Copyright 2009, The Endocrine Society

A vs. B, A vs. C, A vs. D, B vs. C, C vs. D: p < 0.01. B vs. D: p = 0.760